全球血管瘤治療市場規模、份額和趨勢分析報告—產業概況和2032年預測

血管瘤治療市場分析

血管瘤治療市場一直在經歷顯著增長，這得益於醫療治療的進步以及血管瘤患病率的上升，尤其是在嬰兒中。血管瘤是良性血管腫瘤，通常形成於皮膚或內臟器官。治療方法通常是藥物治療、雷射治療，嚴重的情況下還需要手術。隨著β受體阻斷劑、皮質類固醇和新雷射技術等創新治療方法的發展，市場正在不斷擴大，為患者提供更有效、微創的治療選擇。最近，新藥和治療技術的批准增強了治療選擇，改善了患者的治療效果。此外，人們對血管瘤的認識不斷提高，以及CT 掃描和血管攝影等診斷工具的進步，有助於早期發現和及時介入。這增加了對專科治療的需求，特別是兒科護理，並刺激了全球血管瘤治療市場的成長。

血管瘤治療市場規模

2024 年全球血管瘤治療市場規模為 18.6 億美元，預計到 2032 年將達到 24.9 億美元，2025 年至 2032 年預測期內的複合年增長率為 3.70%。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。

血管瘤治療市場趨勢

“醫療技術的進步”

隨著人們認識的提高和醫療技術的進步，血管瘤治療市場正在經歷顯著成長。非侵入性治療的創新，例如雷射療法和β受體阻斷劑等口服藥物，徹底改變了血管瘤的治療，提供了有效的手術替代方案。市場的一個主要趨勢是人們越來越傾向於微創治療，這種治療更安全，需要的恢復時間更短，尤其是對於兒科患者而言。尤其是雷射治療，由於其精確度和副作用較小，因此越來越受歡迎。隨著血管瘤治療研究的不斷深入，市場預計將擴大，出現新的治療選擇，提高療效，改善患者預後，鞏固非手術幹預的趨勢。

報告範圍和血管瘤治療市場細分   

Hemangiomas Treatment Market Definition

Hemangiomas treatment refers to the medical interventions used to manage and reduce the size of hemangiomas, which are benign tumors formed by an abnormal growth of blood vessels. These treatments aim to alleviate symptoms, prevent complications, and in some cases, promote the regression of the hemangioma. Common treatment options include oral medications (such as beta-blockers), laser therapies, surgical procedures, and corticosteroids. The choice of treatment depends on the size, location, and severity of the hemangioma, as well as the age and health of the patient.

Hemangiomas Treatment Market Dynamics

Drivers

• Rising Incidence of Hemangiomas

The growing number of diagnosed hemangioma cases, particularly in infants, is a key driver for the hemangiomas treatment market. Hemangiomas, often appearing shortly after birth, are increasingly being detected due to improved diagnostic tools and greater awareness among healthcare professionals and parents. As these cases rise, there is a higher demand for effective treatments, ranging from oral medications such as beta-blockers to advanced surgical and laser options. The need for targeted therapies that can manage both superficial and deep hemangiomas effectively is growing, driving the development of new treatments and contributing to the market’s expansion.

• Expansion of Pediatric Healthcare

As pediatric healthcare continues to improve worldwide, there is an increased focus on treating hemangiomas in children, fueling the growth of the hemangiomas treatment market in pediatric segments. Advancements in pediatric healthcare, such as better access to medical care, earlier diagnoses, and improved treatment options, have made it easier to manage conditions such as hemangiomas effectively. With a greater emphasis on ensuring healthy child development, parents and healthcare providers are more proactive in seeking treatments that can prevent complications related to hemangiomas. This growing focus on pediatric care is a significant driver of demand for specialized hemangioma therapies tailored to children’s needs.

Opportunities

• Non-Invasive Treatment Demand

人們對非侵入性治療方案（尤其是雷射療法）的日益青睞，為血管瘤治療領域帶來了巨大的市場機會。雷射治療因其能夠精確瞄準血管瘤，最大限度地減少對周圍組織的損害而受到高度青睞。這可以改善美容效果並縮短恢復時間，這是患者和醫療保健提供者的關鍵考慮因素。隨著患者越來越多地尋求比傳統手術侵入性更小的替代治療方法，對雷射療法的需求預計會增加。這種向非侵入性治療的轉變為創新、市場擴張和投資開發先進、有效和可獲得的療法創造了機會。

• 遠距醫療診斷和監測

隨著遠距醫療的日益普及，將遠距會診與血管瘤的診斷、治療計劃和持續監測相結合具有巨大的市場機會。遠距醫療使醫療專業人員能夠進行虛擬評估，從而減少了親自就診的需要，這對於偏遠或服務不足地區的患者尤其有益。這可以增強早期診斷和及時幹預，改善治療效果。此外，遠距醫療能夠實現持續的後續護理，為患者提供更大的便利，並減少旅行時間和相關費用。隨著醫療保健系統的發展，遠距醫療可以在擴大獲得專門血管瘤治療的機會和提高整體患者滿意度方面發揮關鍵作用。

限制/挑戰

• 複雜病例的治療選擇有限

儘管有雷射治療、口服藥物和手術等治療選擇，但血管瘤治療市場面臨的主要挑戰之一是缺乏針對複雜或嚴重病例的有效治療方法。影響內臟或深層組織的血管瘤特別難以治療，因為它們可能需要更專業的方法。目前的治療方法可能並非對所有類型或位置的血管瘤都有效，這限制了其應用。針對更複雜病例的可用治療方法的差距限制了市場成長，並需要持續進行研究和開發以解決血管瘤治療中的這些特定挑戰。

•  先進療法成本高昂

血管瘤治療市場面臨的一個重大限制因素是雷射治療和手術等先進療法的成本高昂。這些程序雖然有效，但費用卻非常昂貴，特別是在醫療保險覆蓋範圍有限或無法涵蓋的地區。對於低收入患者或沒有足夠醫療保險的患者，經濟負擔可能會阻礙他們獲得必要的治療，從而造成護理障礙。這種經濟限制限制了市場範圍，因為相當一部分人口可能無法負擔這些治療。解決這些財務障礙對於擴大血管瘤治療的可近性和確保更廣泛地採用血管瘤治療至關重要。

本市場報告提供了最新發展、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地化市場參與者的影響的詳細信息，分析了新興收入領域的機會、市場法規的變化、戰略市場增長分析、市場規模、類別市場增長、應用領域和主導地位、產品批准、產品發布、地理擴展、市場技術創新。要獲取更多市場信息，請聯繫 Data Bridge Market Research 獲取分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。

血管瘤治療市場範圍

市場根據藥物類別、類型、診斷、治療類型、給藥途徑、最終用戶和分銷管道進行細分。這些細分市場之間的成長將幫助您分析行業中微弱的成長細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。

藥物類別

• β受體阻斷劑藥物
• 抗發炎藥物
• 其他的

類型

• 外部血管瘤
• 內部血管瘤

診斷

• X射線
• 電腦斷層掃描 (CT)
• 活檢
• 血管攝影
• 其他的

治療類型

• 藥物
• 手術
• 雷射治療
• 其他的

給藥途徑

• 口服
• 注射劑
• 其他的

最終用戶

• 醫院
• 居家護理
• 專科診所
• 其他的

分銷管道

• 醫院藥房
• 網路藥局
• 零售藥局
• 其他的

血管瘤治療市場區域分析

對市場進行分析，並按國家、藥物類別、類型、診斷、治療類型、給藥途徑、最終用戶和分銷管道提供市場規模洞察和趨勢，如上所述。

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hemangioma treatment market, driven by a rising incidence of infantile hemangiomas and an increasing number of adult hemangioma cases in the region. The region's advanced healthcare infrastructure and access to specialized treatments contribute to its dominance. In addition, growing awareness and early diagnosis further boost demand for effective therapies in North America.

Europe is projected to experience significant growth in the hemangioma treatment market from 2025 to 2032, fueled by the rising adoption of minimally invasive surgeries. The availability of effective drugs and advanced treatment options in the region further supports this growth. In addition, the increasing focus on patient-centered care and enhanced healthcare access is expected to drive demand for innovative therapies in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Hemangiomas Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Hemangiomas Treatment Market Leaders Operating in the Market Are:

• Pierre Fabre Laboratories (France)
• BIOLASE, Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Cutera, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• IRIDEX Corporation (U.S.)
• Alma Lasers (Israel)
• LINLINE Medical Systems (Israel)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Akorn Operating Company LLC (U.S.)
• Pfizer Inc. (U.S.)

Latest Developments in Hemangiomas Treatment Market

• In March 2024, AstraZeneca's acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates, marks a significant step forward in cancer treatment. These advanced radioconjugates offer a targeted approach to therapy, potentially improving upon traditional methods such as chemotherapy and radiotherapy by enhancing effectiveness and reducing side effects. This strategic acquisition highlights AstraZeneca's commitment to revolutionizing oncology research and underscores its goal of reshaping cancer care with innovative therapeutic solutions
• In June 2023, Candela Corporation announced an expansion of its FDA-cleared Vbeam Family of Pulsed Dye Lasers (PDL) to include the 595 nm wavelength for treating pediatric patients with cutaneous capillary malformations, such as port wine stains (PWS), as well as infantile and congenital hemangiomas
• In July 2023, the American Society for Laser Medicine and Surgery (ASLMS) collaborated with the Vascular Birthmarks Foundation (VBF) and an international, multidisciplinary team to establish consensus guidelines for the use of laser therapy in treating vascular birthmarks
• In December 2021, research led by the Centenary Institute and Harvard Medical School revealed that a compound found in current beta-blocker treatments could be repurposed to enhance both the safety and effectiveness of therapies for infantile hemangiomas

SKU-50413